While there are no clinically approved drugs directly targeting KRAS, several indirect KRAS inhibitors—targeting proteins that support oncogenic KRAS functionality, rather than targeting KRAS itself—demonstrate encouraging results in other cancers yet remain unable to appreciably improve pancreatic cancer outcomes. This evidence concerns the gene KRAS and cancer.